Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CanISleepinMS: Cannabidiol for sleep quality in multiple sclerosis (series of N-of-1 trials)
2022-002372-36Phase 2Active
- Sponsor
- Wageningen Research
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Insomnia and multiple sclerosis (MS) comparing Cannabidiol periods with Placebo periods (2 arms). Primary endpoint: Insomnia Severity Index score. Started Sep 2024; status: active.
02
Drugs
cannabidiol
03
Conditions
Insomniamultiple sclerosis (MS)
Beyond the preview
Go deeper on 2022-002372-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002372-36.